These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11224953)

  • 21. Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia.
    Reilly DR; Delva NJ; Hudson RW
    Can J Psychiatry; 2000 Aug; 45(6):559-63. PubMed ID: 10986575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment?
    Thibaut F; Cordier B; Kuhn JM
    Psychoneuroendocrinology; 1996 May; 21(4):411-9. PubMed ID: 8844879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Urolithiasis in the Long-Term GnRH Agonist Treatment of Patients with Paraphilia: 3 Case Studies].
    Mayrhofer G; Wegner D; Voß T
    Aktuelle Urol; 2016 Dec; 47(6):487-490. PubMed ID: 27701680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy.
    Marumo K; Baba S; Murai M
    Int J Urol; 1999 Jan; 6(1):19-23. PubMed ID: 10221860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: the management of bone demineralization associated with long-term treatment of multiple paraphilias with long-acting LHRH agonists.
    Dickey R
    J Sex Marital Ther; 2002; 28(3):207-10. PubMed ID: 11995599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A placebo-controlled trial of the antiandrogen cyproterone acetate in deviant hypersexuality.
    Cooper AJ
    Compr Psychiatry; 1981; 22(5):458-65. PubMed ID: 6230209
    [No Abstract]   [Full Text] [Related]  

  • 27. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
    de Voogt HJ
    Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.
    Hoda MR; Kramer MW; Merseburger AS; Cronauer MV
    Expert Opin Pharmacother; 2017 Jan; 18(1):105-113. PubMed ID: 27826989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
    J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk?
    Huygh J; Verhaegen A; Goethals K; Cosyns P; De Block C; Van Gaal L
    Crim Behav Ment Health; 2015 Jul; 25(3):226-30. PubMed ID: 25851640
    [No Abstract]   [Full Text] [Related]  

  • 32. Sadistic homosexual pedophilia treatment with cyproterone acetate.
    Cooper AJ; Baxter D; Wong W; Losztyn S
    Can J Psychiatry; 1987 Nov; 32(8):738-40. PubMed ID: 2961433
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism.
    Rousseau L; Couture M; Dupont A; Labrie F; Couture N
    Can J Psychiatry; 1990 May; 35(4):338-41. PubMed ID: 2189544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonists of luteinizing hormone-releasing hormone in prostate cancer.
    Rick FG; Block NL; Schally AV
    Expert Opin Pharmacother; 2013 Nov; 14(16):2237-47. PubMed ID: 23984804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyproterone acetate for male hypersexuality.
    Davies TS
    J Int Med Res; 1974; 2(2):159-63. PubMed ID: 4468912
    [No Abstract]   [Full Text] [Related]  

  • 37. Relative effectiveness of alternative androgen withdrawal therapies in initiating regression of rat prostate.
    Rennie PS; Bruchovsky N; Goldenberg SL; Lawson D; Fletcher T; Foekens JA
    J Urol; 1988 Jun; 139(6):1337-42. PubMed ID: 2967378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cyproteronacetat treatment of sexual offenders.
    Berner W; Brownstone G; Sluga W
    Neurosci Biobehav Rev; 1983; 7(3):441-3. PubMed ID: 6230546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of cyproterone acetate in prostate cancer.
    Goldenberg SL; Bruchovsky N
    Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
    Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
    BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.